AiVita Biomedical

AiVita Biomedical

Private
Irvine, CaliforniaHealthcare & Life Scienceswww.aivitabiomedical.com

Last Round

Series B

Extension

Dec 29, 2020

Total Funding Raised

$48.25M

Company Overview

AiVita Biomedical is a biotechnology company focused on advancing commercial and clinical-stage programs through curative and regenerative medicines, including the development of personalized vaccines for infectious diseases and cancer treatment, as well as innovative vaccine kits for pathogen readiness against emerging threats.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, D2C Brands, Fashion & Beauty, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

personalized immunotherapycancer vaccinestem cell manufacturingcell therapyclinical-stage biotechglioblastoma treatmentovarian cancer treatmentdendritic cell vaccinestem cell therapystem cell skincareregenerative medicineautologous cell therapyregen medcosmeceuticalsbiotech skincaremacular degenerationclinical skincaredirect-to-consumer skincare

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AiVita Biomedical Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AiVita Biomedical Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionDec 29, 2020
Series BFeb 25, 2020
GrantJul 17, 2018
Series BJun 11, 2018
GrantSep 29, 2016
Grant
Jul 7, 2016

Key People

Founding team and executive leadership

Scott R. Burell

Chief Financial Officer

Executive Team

AiVita Biomedical Investors

Notable investors and investment history

AiVita Biomedical Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AiVita Biomedical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AiVita Biomedical's valuation, stock price, and market status.

Firmographic Details

HeadquartersIrvine, California
Employee Range21
Year Founded2016
Last FundingDec 29, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.